Enzyme response shearing type magnetic DNA nanogel as well as preparation method and application thereof

Through the enzyme-responsive shear magnetic DNA nanogel loaded cisplatin prodrug, the enzyme-responsive activation and release drugs in the tumor microenvironment is used to solve the problem of difficulty in accumulation and infiltration of nanodrugs in the tumor, and the accuracy of tumor treatment is achieved and High efficiency reduces damage to normal tissue.

CN118903473APending Publication Date: 2024-11-08SHANGHAI INST OF ONCOLOGY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410956016.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-17
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

In existing tumor treatments, nanodrugs are difficult to effectively accumulate and infiltrate in the tumor, resulting in low drug bioavailability and anti-tumor efficacy, and targeted drugs also have side effects on normal cells.

Method used

The enzyme-responsive shear magnetic DNA nanogel is used to form a targeted DNA gel through RCA rolling ring amplification technology combined with magnetic iron oxide nanoparticles, and is loaded with cisplatin bioorthogonal prodrug, and is activated using enzyme-responsiveness in the tumor microenvironment. Release drugs to achieve accurate and controlled release of drugs.

Benefits of technology

It improves the bioavailability of the drug and anti-tumor efficacy, reduces the toxic side effects on normal cells, and significantly improves the tumor treatment effect, especially in the precise treatment of breast cancer, which significantly improves the efficacy and reduces damage to normal tissues.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903473A_ABST
    Figure CN118903473A_ABST
Patent Text Reader

Abstract

The invention provides enzyme response shearing type magnetic DNA (deoxyribonucleic acid) nanogel. The enzyme response shearing type magnetic DNA nanogel is prepared from deoxyribonucleic acid nanogel, biotin modified deoxyribonucleic acid, ferroferric oxide nanoparticles modified by streptavidin, poly L-arginine, regularly spaced clustered short palindromic repetitive sequence associated genes and guide ribonucleic acid. The invention also provides a preparation method of the DNA nanogel. The invention also provides application of the enzyme response shear type magnetic DNA nanogel in preparation of drugs for treating cancers and application of the enzyme response shear type magnetic DNA nanogel as a drug carrier. The enzyme response shear type magnetic DNA nanogel can efficiently load and deliver an anti-cancer prodrug in a targeted manner, enzyme response shear release is realized through a tumor microenvironment, and targeted precise controlled release of the nano-drug can be effectively realized. The preparation method is simple, convenient and suitable for large-scale production.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of bioengineering and relates to a DNA nanogel, in particular to an enzyme-responsive shearing magnetic DNA nanogel and a preparation method and application thereof. Background Art

[0002] Among the malignant tumors in Chinese women, the incidence of breast cancer ranks first, and its incidence rate is increasing year by year. At present, the main methods for clinical treatment of tumors are surgical resection, radiotherapy, chemotherapy and molecular targeted therapy. However, surgical resection is generally suitable for early and mid-term, and radiotherapy is used as a local treatment to control the progression of local lesions. Chemotherapy is a non-selective killing treatment that has obvious damage to tumors and normal cells and organ tissues, resulting in side effects. Molecular targeted therapy refers to the specific intervention of drugs on specific targets such as protein molecules, genes or pathways on cancer cells at the molecular level, causing cancer cells to die or lose function. However, due to individual differences, not everyone is suitable for treatment with targeted drugs. Molecular targeted drugs are prone to drug resistance and off-target effects, affecting the ideal efficacy of the drug. Therefore, precision treatment of cancer is an effective means to reduce cancer deaths and improve the quality of life of patients.

[0003] With the rapid development of nanotechnology, the design of nanomedicines using nanocarriers in specific environments such as hypoxia, low pH, and dense tumor angiogenesis has attracted widespread attention. Nanomedicines can specifically identify tumors, effectively improve the intracellular enrichment of drug delivery in tumor tissues, and improve the bioavailability and anti-tumor effect of drugs. At present, some nanomedicines, such as paclitaxel liposomes (Lipusu) and mitoxantrone hydrochloride liposome injection (Doenda), have entered the clinic for tumor treatment and have achieved better efficacy than simple free drugs, but there is still a gap from the ideal efficacy. One of the main reasons is the low concentration and weak permeability of targeted drugs in tumor treatment. The proliferation of dense extracellular matrix and interstitial tissue in the tumor microenvironment makes it difficult for nanomedicines to effectively accumulate and infiltrate in tumors, and it is difficult to effectively enter cells and release, which greatly reduces the bioavailability and anti-tumor efficacy of drugs. Therefore, in order to solve the above problems, the establishment of a nano drug delivery system with high tumor permeability, targeted enrichment, and specific site-controlled release has important clinical application significance for effectively improving the bioavailability of anti-tumor drugs and exerting anti-tumor efficacy.

[0004] Carrier materials play a vital role in the construction of nanomedicines, and they should have good biosafety, versatility, operability and convenient preparation. Deoxyribonucleic acid (DNA) is a biomacromolecule that is not only a carrier of genetic information, but also a very suitable material for the construction of drug delivery carriers. Compared with other polymers, DNA has many superior properties, such as specific molecular recognition, precise size regulation, excellent biocompatibility and biodegradability. DNA can be precisely manipulated to construct drug carriers in nanoparticles and hydrogels through base complementary pairing, crosslinking with enzymes, and physical entanglement triggered by rolling circle amplification (RCA). DNA is composed of nucleotides, and the final product of degradation is pentose and other substances necessary for human metabolism. It has particularly excellent biosafety and shows great potential in biomedical fields such as drug controlled release, biosensing, and tissue engineering. Cisplatin is usually utilized by forming inter- and intra-strand crosslinks with DNA, resulting in tumor cell DNA damage and cell apoptosis. However, cisplatin indiscriminately damages both tumor cells and normal cells, and exhibits dose-limiting side effects such as acute nephrotoxicity and hepatotoxicity, which largely limits its clinical treatment. Bioorthogonal cisplatin prodrug can be activated into cisplatin by the high concentration of GSH in the tumor microenvironment, significantly reducing the toxic side effects of the drug on normal cells and achieving effective treatment of specific tumor sites. Summary of the invention

[0005] In view of the above technical problems in the prior art, the present invention provides an enzyme-responsive shearing magnetic DNA nanogel and a preparation method and application thereof. The enzyme-responsive shearing magnetic DNA nanogel and a preparation method and application thereof are intended to solve the technical problem that the drug treatment effect of tumors in the prior art is poor.

[0006] The present invention provides an enzyme-responsive shearing magnetic DNA nanogel, wherein the nanogel is composed of deoxyribonucleic acid nanogel (DNA-nanogel), biotin-modified deoxyribonucleic acid (DNA-biotin), streptavidin-modified ferroferric oxide nanoparticles (SA-Fe3O4 The invention discloses a novel nanoparticle-based method for preparing ...

[0007] Furthermore, the particle size of the magnetic DNA nanogel is 100-300 nm.

[0008] Furthermore, it also contains cisplatin prodrug. In the DNA nanogel, the molar ratio of the deoxynucleic acid nanogel to the cisplatin prodrug is 1:30-800.

[0009] Furthermore, the DNA nanogel is in a spherical shape.

[0010] Furthermore, the sequence of the biotin-modified deoxyribonucleic acid is:

[0011] 5'-biotin-GACAGGCCCGAAGGAATAGAAGAAGAAGGTGGAGAGAGAG-3';

[0012] The sequence of the guide RNA is:

[0013] 5'-GAAGGAAUAGAAGAAGAAGGguuuuagagcuagaaauagcaaguuaaaauaaggcuaguccg uuaucaacuugaaaaaguggcaccgagucggugcu-3';

[0014] The present invention also provides a method for preparing the enzyme-responsive shearing magnetic DNA nanogel, comprising the following steps:

[0015] 1) Mix the specific ssDNA and primer 1 in a T4 ligase buffer at a molar ratio of 1:1, cool the mixture to 4°C at a gradient of -1°C / min at 95°C, then add T4 ligase and ATP to the reaction solution, and react at 4°C overnight to obtain a circular DNA structure as the reaction product;

[0016] 2) Weigh the reaction product circular DNA structure and dNTP, wherein the dNTP is a general term for dATP, dCTP, dGTP and dTTP, the concentration of the circular DNA structure is 30 μM, and the concentration of the dNTP is 100 mM, and mix them in phi29 buffer according to the volume ratio of the circular DNA structure and dNTP of 1 to 5:1, then add DTT and phi29 polymerase, react at 40°C for 0.5 to 1h, and then add streptavidin-modified ferric oxide nanoparticles and biotin-modified deoxyribonucleic acid complexes, The molar ratio of the deoxyribonucleic acid nanogel to the biotin-modified deoxyribonucleic acid sequence is 1:1-50; the mass ratio of the streptavidin-modified ferric oxide nanoparticles to the biotin-modified deoxyribonucleic acid is 1:1-10; then, primer 2 and primer 3 are added, the molar ratio of the primer 2, primer 3 and the circular DNA structure is 1:1:0.1-3, the concentration of the primer 2 and primer 3 is 100-500 μM, and the reaction is carried out at 40°C for 0.5-1h to obtain the magnetic nanogel; the gel is dispersed and then centrifuged at high speed to remove the solution;

[0017] 3) adding poly-L-arginine, wherein the molar ratio of the deoxyribonucleic acid nanogel to the poly-L-arginine is 1:1-100; uniformly dispersing by ultrasonication, reacting at 4°C for 12-20 hours, and then removing unreacted poly-L-arginine by high-speed centrifugation;

[0018] 4) adding clustered regularly interspaced short palindromic repeats-associated genes and guide RNA complexes, wherein the molar ratio of the deoxyribonucleic acid nanogel to the clustered regularly interspaced short palindromic repeats-associated genes is 1:1-10; the molar ratio of the clustered regularly interspaced short palindromic repeats-associated genes to the guide RNA complex is 1:1, reacting overnight at 4°C, and removing unreacted CRISPR-Cas9 and sgRNA complexes by high-speed centrifugation to obtain an enzyme-responsive shearing magnetic DNA nanogel.

[0019] In step 2), before adding streptavidin-modified ferroferric oxide nanoparticles and biotin-modified deoxyribonucleic acid complexes, cisplatin prodrug is added, and the molar ratio of the deoxyribonucleic acid nanogel to the cisplatin prodrug is 1:30-800.

[0020] Furthermore, in step 2), the final concentration of the phi29 polymerase is 0.1U / uL, and the final concentration of the DTT is 2mM.

[0021] Further, the sequence of the ssDNA is: 5'-Phosphate-TCGTTTGATGTTCCTAACGTA CCAACGCACACGCAGTATTATGGACTGGTAAAAGCTTGACAGGCCCGAAGGAATAG AAGAAGAAGGTGGAGAGAGAGAGGCATTGGCTG-3';

[0022] The sequence of primer 1 was: 5′-TAGGAACATCAAACGACAGCCA-3′;

[0023] The sequence of primer 2 was: 5′-ACGCAGTATTATGGACTG-3′;

[0024] The sequence of primer 3 is: 5'-TGGTACGTTAGGAACATC-3'.

[0025] Specifically, using the method of the present invention, the reaction product is collected by centrifugation and purified by washing with distilled water.

[0026] The present invention also provides the use of the enzyme-responsive shearing magnetic DNA nanogel in preparing a drug for treating cancer.

[0027] Furthermore, the cancer is triple-negative breast cancer.

[0028] The present invention also provides the use of the enzyme-responsive shearing magnetic DNA nanogel in preparing anti-tumor drug carriers.

[0029] The present invention utilizes RCA rolling circle amplification technology, and in this process combines magnetic iron oxide nanoparticles (Fe3O4 NPs) to form a magnetic response targeted DNA gel as a delivery carrier. The magnetic DNA nanogel with a specific coding sequence can be rapidly sheared by enzyme response to achieve precise and controllable release of anti-tumor drugs. In addition, the magnetic DNA nanogel loaded with cisplatin bioorthogonal prodrug can respond to activation and release drugs in a specific tumor microenvironment, thereby achieving the functions of precise drug release and reactive activation, thereby improving the bioavailability of the drug, enhancing the anti-tumor efficacy, and reducing drug toxicity. Therefore, the design of multifunctional therapeutic targeted nanomedicines using magnetic DNA gel carriers is of great significance for the precise treatment of breast cancer by responding to the tumor microenvironment and shearing with enzyme response to achieve rapid and precise release of anti-tumor bioorthogonal drugs. PLA and Cas9 / sgRNA are non-covalently assembled into magnetic DNA nanogels, which effectively solves the problems of low drug-targeted tumor concentration and weak permeability in other nanomedicines.

[0030] The enzyme-responsive shearing magnetic DNA nanogel (MG / PLA / Cas9-sgRNA) of the present invention is prepared by combining poly-L-arginine (PLA), regularly spaced clustered short palindromic repeats (CRISPR-Cas9) and guide RNA (sgRNA) in a magnetic DNA nanogel (MG) structure through non-covalent bonds, and the preparation method is simple and highly repeatable. Different from the traditional nanomedicine constructed by assembly, PLA and CRISPR-Cas9 / sgRNA are non-covalently bound to the magnetic DNA nanogel, which effectively solves the problem that the small molecule targeted concentration in other nanomedicines is low and the permeability is weak, making it difficult to effectively accumulate and infiltrate in the tumor, and helps to improve the bioavailability and anti-tumor efficacy of nanomedicines. As a response regulating component, PLA can release gas in the tumor microenvironment reaction to promote the deep penetration of magnetic DNA nanogel in tumor tissue, and the structural change promotes the separation and enrichment of Cas9-sgRNA, realizing enzyme response shearing. Moreover, Cas9 / sgRNA can specifically shear the specific coding sequence sites of magnetic DNA nanogels, realize the rapid release of cisplatin prodrugs, significantly improve the bioavailability of anti-tumor drugs, and efficiently exert the tumor killing effect of drugs. In addition, the present invention activates anti-tumor cisplatin prodrugs through glutathione reduction response in the tumor microenvironment, realizes precise killing only for tumor tissues, significantly improves the tumor treatment effect, and reduces damage to normal tissues. Combined with anti-tumor bioorthogonal drugs, enzyme-responsive shearing magnetic DNA nanogels can effectively treat breast cancer.

[0031] Compared with the prior art, the technical effect of the present invention is positive and obvious. The enzyme-responsive shearing magnetic DNA nanogel of the present invention can efficiently load and target the delivery of anticancer drug prodrugs, realize enzyme-responsive shearing release through the tumor microenvironment, and effectively control the targeted and precise release of nano-drugs. The ferroferric oxide nanoparticles on the surface of the magnetic DNA nanogel can achieve tumor site targeting of triple-negative breast cancer, and can be combined with anticancer drug prodrugs to deliver targets to play a role, only targeting tumor tissues to accurately kill, significantly improve tumor treatment effects, and reduce damage to normal tissues. The preparation method of the present invention is simple and suitable for large-scale production. The present invention provides new ideas and effective ways for the precise treatment of breast cancer, which is expected to solve the problems of low drug delivery efficiency and large damage to normal tissues in the treatment of breast cancer, and also provides technical guidance and method reference for the treatment of other tumors and related diseases. BRIEF DESCRIPTION OF THE DRAWINGS

[0032] Figure 1 Scanning electron microscopy images of gel formation based on RCA and MCA.

[0033] Figure 2 Agarose gel electrophoresis diagram of DNA nanogel synthesis.

[0034] Figure 3 Transmission electron microscopy images of MG and MG / PLA / Cas9-sgRNA and their release in response to tumor microenvironment regulation.

[0035] Figure 4 Size characterization and structural surface potential map of MG / PLA / Cas9-sgRNA.

[0036] Figure 5 The cytotoxicity of MG(Pt) / PLA / Cas9-sgRNA to human breast cancer cells MDA-MB-231.

[0037] Figure 6 This study studies the killing effects of MG, MG(Pt), MG(Pt) / PLA, and MG(Pt) / PLA / Cas9-sgRNA on human breast cancer cells MDA-MB-231.

[0038] Figure 7 The flow cytometric detection of apoptosis of human breast cancer cells MDA-MB-231 by MG, MG(Pt), MG(Pt) / PLA, and MG(Pt) / PLA / Cas9-sgRNA.

[0039] Figure 8 This is a comparison chart of MG, MG(Pt), MG(Pt) / PLA, and MG(Pt) / PLA / Cas9-sgRNA inhibiting tumor growth in breast cancer mice. DETAILED DESCRIPTION

[0040] The present invention is described in detail below in conjunction with specific embodiments. The following embodiments will help those skilled in the art to further understand the present invention, but are not intended to limit the present invention in any form. The methods are conventional methods unless otherwise specified. The raw materials can be obtained from public commercial channels unless otherwise specified. It should be noted that, for those of ordinary skill in the art, several variations and improvements can also be made without departing from the concept of the present invention. These all belong to the scope of protection of the present invention.

[0041] Explanation of symbols:

[0042] DTT: dithiothreitol;

[0043] ATP: adenosine triphosphate (ATP for short);

[0044] SA-Fe3O4 NPs: streptavidin-modified ferrosoferric oxide nanoparticles;

[0045] RCA: rolling circle amplification;

[0046] MCA: multiprimer chain amplification;

[0047] MG: magnetic nanogel;

[0048] PLA: poly-L-arginine;

[0049] MG(Pt): magnetic nanogel loaded with cisplatin prodrug;

[0050] MG(Pt) / PLA: magnetic nanogel modified with polyarginine loaded with cisplatin prodrug;

[0051] MG(Pt) / PLA / Cas9-sgRNA: cisplatin prodrug-loaded magnetic nanogel modified with polyarginine and Cas9 / sgRNA complex;

[0052] Log C: logarithm of concentration;

[0053] Ctr: control;

[0054] PI: propidium iodide;

[0055] Annexin V: Annexin V.

[0056] Biotin-modified deoxyribonucleic acid sequence (DNA-biotin) 5′-biotin-GACAGGCCCGAAGGAATAGAAGAAGAAGGTGGAGAGAGAG-3′ (SEQ ID NO. 5) was purchased from Shanghai Sangon Biotechnology Co., Ltd.;

[0057] Streptavidin-modified ferroferric oxide nanoparticles (SA-Fe3O4 NPs) were purchased from Xi'an Ruixi Biotechnology Co., Ltd.;

[0058] Poly-L-arginine (PLA) was purchased from Sigma-Aldrich (Shanghai) Trading Co., Ltd.;

[0059] Clustered regularly interspaced short palindromic repeats-associated gene (CRISPR-Cas9) was purchased from NEW ENGLAND Biolabs (Beijing);

[0060] Guide RNA (sgRNA) (SEQ ID NO. 6): 5′-GAAGGAAUAGAAGAAGAAGGgu uuuagagcuagaaauagcaaguuaaaauaaaggcuaguccguuaucaacuugaaaaaguggcaccgagucggugcu-3′), purchased from Shanghai Sangon Biotechnology Co., Ltd.;

[0061] Cisplatin prodrug was purchased from Shanghai Nafu Biotechnology Co., Ltd.

[0062] Example 1 Preparation of DNA Nanogel Based on RCA and MCA

[0063] Primer 1 (5'-TAGGAACATCAAACGACAGCCA-3' (SEQ ID NO.1)) (5 ​​μl, 10 μM) and ssDNA (5'-Phosphate-TCGTTTGATGTTCCTAACGTACCAACGCACACGCAGTATT ATGGACTGGTAAAAGCTTGACAGGCCCGAAGGAATAGAAGAAGGTGGAGAGA GAGAGGCATTGGCTG-3' (SEQ ID NO.2)) (5 ​​μl, 10 μM) were mixed in T4 ligase buffer solution, and the temperature was gradually reduced from 95°C to 4°C (-1°C / min) in a PCR instrument. T4 ligase (1.25 μl, 400000 U / ml) and ATP (1.25 μl, 50 mM) were added to the solution and mixed well. The mixture was reacted at 4°C overnight to prepare circular DNA.

[0064] Take 5 μl circular DNA (30 μM), add 1.25 μl dATP (100 mM), 1.25 μl dCTP (100 mM), 1.25 μl dGTP (100 mM), 1.25 μl dTTP (100 mM) and 1 μl DTT (100 mM) to the phi29 buffer solution, and finally add 0.5 μl 10 U / μl phi29 DNA polymerase.

[0065] The mixed solution was reacted at 40°C for 0.5h to 4h, and then primer 2 (5'-ACGCAGTATTATGGACT G-3' (SEQ ID NO.3)) (0.5μl, 500μM) and primer 3 (5'-TGGTACGTTAGGAACATC-3' (SEQ ID NO.4)) (0.5μl, 500μM) were added, and the mixture was reacted at 40°C for another 0.5h to 16h to obtain DNA-Nanogel.

[0066] The morphology of DNA nanogel was observed using Zeiss Gemini scanning electron microscope. The test results are as follows: Figure 1 As shown, the prepared nanomedicine has a spherical structure, good dispersibility, and the particle size can be controlled at about 100-5000 nanometers.

[0067] Example 2 Characterization and magnetic functionalization of DNA nanogels, enzyme-responsive modification and regulation of shear-responsive release

[0068] For agarose gel electrophoresis (AGE) analysis, 0.3 g of agarose was added to 30 ml of 1x TAE buffer solution to prepare a 1% agarose gel.

[0069] 10 μl DNA sample (Marker, ssDNA, Primer1, Primer2, Primer3, Nanogel) and 2 μl nucleic acid dye (6x, YeaRed). Add 10 μl sample to each well, run at 120V for 50 minutes, and then image with Bio-Rad chemiluminescence system. The results are shown in Figure 2 shown.

[0070] Magnetic functionalization synthesis of DNA nanogels (MG):

[0071] Take 5 μl circular DNA (30 μM), add 1.25 μl dATP (100 mM), 1.25 μl dCTP (100 mM), 1.25 μl dGTP (100 mM), 1.25 μl dTTP (100 mM) and 1 μl DTT (100 mM) to the phi29 buffer solution, and finally add 0.5 μl 10 U / μl phi29 DNA polymerase.

[0072] After the mixed solution was reacted at 40°C for 0.5 h to 4 h, cisplatin prodrug (4 μl, 10 mM) was added, and then 20 μl (total volume) of a mixed solution of biotin-labeled DNA (14 μl 100 μM) and streptavidin-modified ferroferric oxide nanoparticles with a size of 10 nm (6 μl, 1 mg / ml) was added, and then 0.5 μl 100 μM primer 2 (5'-ACG CAGTATTATGGACTG-3') and 0.5 μl 100 μM primer 3 (5'-TGGTACGTTAGGAACATC-3') were added to the mixed reaction solution, and the reaction was carried out at 40°C for 0.5 h. The transmission electron microscopy characterization of the synthesized structure is shown in FIG. Figure 3 As shown in A (MG).

[0073] The DNA magnetic nanogel (MG) was centrifuged at high speed (12000 rpm, 20 min), the upper layer solution was removed, and 50 μl of poly-L-arginine (1 mg / ml, molar number 7×10 -10 ~3×10 -9 mol), reacted at 4°C for 16h, and then centrifuged at high speed (15000rpm, 30min) to remove excess poly-L-arginine solution to obtain MG / PLA. Then 200μl CRISPR-Cas9 and sgRNA complex (both at a concentration of 1μM, a molar ratio of 1:1) were added, reacted overnight at 4°C, and then centrifuged at high speed (15000rpm, 30min) to remove excess CRISPR-Cas9 and sgRNA complex to obtain MG / PLA / Cas9-sgRNA, and then deionized water was added for ultrasonic dispersion, and TEM was used to characterize the complex. Figure 3 As shown in B. Regulated shear release The synthesized MG / PLA / Cas9-sgRNA was added to a 0.1 mM PBS solution (pH 6.5) containing 100 μM H2O2 for 4 h and then characterized by TEM. Figure 3 As shown in C.

[0074] Example 3 Size and potential characterization of enzyme-responsive shearing magnetic DNA nanogels

[0075] The size and surface potential of MG / PLA / Cas9-sgRNA (1 mL) synthesized in Example 2 were measured by laser nanoparticle size analyzer (DLS). The results are as follows: Figure 4As shown, the average particle sizes of MG, MG / PLA and MG / PLA / Cas9-sgRNA were 183.7nm, 196.4nm and 210.6nm, respectively; the average surface potentials of MG, MG / PLA and MG / PLA / Cas9-sgRNA were -27.67mV, +71.10mV and -19.57mV, respectively, indicating that the MG / PLA / Cas9-sgRNA structure was synthesized.

[0076] Example 4 Cytotoxicity of enzyme-responsive shearing magnetic DNA nanogels to human MDA-MB-231 breast cancer cells

[0077] Breast cancer MDA-MB-231 cells in the logarithmic growth phase were taken and 1×10 4 The cells were inoculated into a 96-well plate at a density of 100 μL of culture medium, and cultured overnight at 37°C and 5% CO2. Then, 100 μL of MG(Pt) / PLA / Cas9-sgRNA of different concentrations (0, 5, 25, 50, 100, and 500 μg mL -1 ) for 24 hours. Discard the supernatant, rinse twice with sterile saline at room temperature, add 100 μL of culture medium containing 10 μL of CCK-8 working solution to each well, incubate in a 37°C incubator in the dark for 1 to 2 hours (depending on the cell condition), and when the absorbance value of the blank control group is about 1, measure the absorbance value of each sample at a wavelength of 450 nm with an enzyme marker.

[0078] The experimental results are shown in Figure 5. Compared with the control group, the concentration of MG(Pt) / PLA / Cas9-sgRNA at 50 μg mL -1 When the concentration of 1% β-catenin was 0.14, the activity of breast cancer MDA-MB-231 cells decreased significantly, and the IC50 value was calculated to be 37.34 μg mL -1 , indicating that enzyme-responsive shearing DNA nanogels have obvious cytotoxicity to tumor cells.

[0079] Example 5 The killing effect of enzyme-responsive shearing magnetic DNA nanogel on human MDA-MB-231 breast cancer cells

[0080] Breast cancer MDA-MB-231 cells in the logarithmic growth phase were taken and 1×10 4 The cells were inoculated in a 96-well plate at a density of 100 μL, and then treated with 100 μL of the same concentration sample group (Ctr, MG, MG(Pt), MG(Pt) / PLA, MG(Pt) / PL A / Cas9-sgRNA) (Example 2) for 24 h. The absorbance value of each sample was measured at a wavelength of 450 nm on an ELISA reader using a CCK-8 kit.

[0081] The cell viability was calculated using the following formula: cell viability = (absorbance value of the experimental group - absorbance value of the blank) / (absorbance value of the control group - absorbance value of the blank).

[0082] The experimental results are as follows Figure 6 As shown, there is a significant difference in the cell activity between MG(Pt) / PLA / Cas9-sgRNA and the control group, indicating that the enzyme-responsive shearing DNA nanogel has a good killing effect on tumor cells.

[0083] Example 6 Effect of enzyme-responsive shearing magnetic DNA nanogel on apoptosis of human MDA-MB-231 breast cancer cells

[0084] Breast cancer MDA-MB-231 cells in the logarithmic growth phase were taken and 1.5×10 5 The cells were inoculated in a 12-well plate at a density of 10 cells / mL and cultured overnight at 37°C and 5% CO2, and then treated with different experimental groups (Ctr, MG, MG(Pt), MG(Pt) / PLA, MG(Pt) / PLA / Cas9-sgRNA) (Example 2) for 24 h. The cells were then collected, stained with PI and Annexin V using the Annexin V-FITC apoptosis detection kit (BD, USA), and then apoptosis was detected by flow cytometry (LSRFortessa X-20, BD, USA).

[0085] The experimental results are as follows Figure 7 As shown, there is a significant difference in the cell apoptosis effect between MG(Pt) / PLA / Cas9-sgRNA and the control group, indicating that the enzyme-responsive shearing magnetic DNA nanogel has a significant apoptotic effect on human MDA-MB-231 breast cancer cells.

[0086] Example 7 Antitumor activity of enzyme-responsive shearing magnetic DNA nanogel against mouse breast cancer

[0087] To evaluate the antitumor activity of enzyme-responsive shearing DNA nanogels in breast cancer MDA-MB-231 cell-bearing mice, when the tumor volume was close to 150 mm 3 At the same time, the mice were randomly divided into 6 groups (n=5) and injected with Ctr, MG, MG(Pt), MG(Pt) / PLA, MG(Pt) / PLA / Cas9-sgRNA, and MG(Pt) / PLA / Cas9-sgRNA (Example 2) magnetic field targeting (3 times, every other day) by tail vein injection. The tumor volume and body weight of each mouse were recorded every other day.

[0088] The formula for calculating tumor volume is V = 0.5 × L × W 2, where L is the length and W is the width. Finally, the mice were euthanized, and the tumors were removed and weighed.

[0089] like Figure 8 As shown, MG(Pt) / PLA / Cas9-sgRNA can effectively inhibit the growth of breast cancer tumors in mice compared with the control group.

Claims

1. An enzyme-responsive shearing magnetic DNA nanogel, characterized in that: The nanogel comprises a deoxyribonucleic acid nanogel, biotin-modified deoxyribonucleic acid, streptavidin-modified ferroferric oxide nanoparticles, poly-L-arginine, regularly spaced short palindromic repeat sequence-associated genes and guide RNA; the molar ratio of the deoxyribonucleic acid nanogel to the biotin-modified deoxyribonucleic acid sequence is 1:1-50; the mass ratio of the streptavidin-modified ferroferric oxide nanoparticles to the biotin-modified deoxyribonucleic acid is 1:1-10; the molar ratio of the deoxyribonucleic acid nanogel to poly-L-arginine is 1:1-100; the molar ratio of the deoxyribonucleic acid nanogel to the regularly spaced short palindromic repeat sequence-associated genes is 1:1-10; and the molar ratio of the regularly spaced short palindromic repeat sequence-associated genes to the guide RNA is 1:

1.

2. The enzyme-responsive shearing magnetic DNA nanogel according to claim 1, characterized in that: The particle size of the magnetic DNA nanogel is 100-300nm.

3. The enzyme-responsive shearing magnetic DNA nanogel according to claim 1, characterized in that: The invention also contains cisplatin prodrug. In the DNA nanogel, the molar ratio of the deoxynucleic acid nanogel to the cisplatin prodrug is 1:30-800.

4. The enzyme-responsive shearing magnetic DNA nanogel according to claim 1, characterized in that: The sequence of the biotin-modified deoxyribonucleic acid is: 5'-biotin-GACAGGCCCGAAGGAATAGAAGAAGAAGGTGGAGAGAGAG-3'; The sequence of the guide RNA is: 5’- GAAGGAAUAGAAGAAGAAGGguuuuagagcuagaaauagcaaguuaaaauaaggcuaguccguua ucaacuugaaaaaguggcaccgagucggugcu-3'.

5. The method for preparing the enzyme-responsive shearing magnetic DNA nanogel according to claim 1, characterized in that The steps include: 1) Mix the specific ssDNA and primer 1 in a T4 ligase buffer at a molar ratio of 1:1, cool the mixture to 4°C at a gradient of -1°C / min at 95°C, then add T4 ligase and ATP to the reaction solution, and react at 4°C overnight to obtain a circular DNA structure as the reaction product; 2) Weigh the reaction product circular DNA structure and dNTP, the dNTP is a general term for dATP, dCTP, dGTP and dTTP, the concentration of the circular DNA structure is 30 μM, and the concentration of the dNTP is 100 mM. M, mixing the circular DNA structure and dNTP in a volume ratio of 1 to 5:1 in phi29 buffer, then adding DTT and phi29 polymerase, reacting at 40°C for 0.5 to 1h, then adding streptavidin-modified ferric oxide nanoparticles and biotin-modified deoxyribonucleic acid complexes, the molar ratio of the deoxyribonucleic acid nanogel to the biotin-modified deoxyribonucleic acid sequence is 1:1 to 50; the mass ratio of the streptavidin-modified ferric oxide nanoparticles to the biotin-modified deoxyribonucleic acid is 1:1 to 10; then adding primer 2 and primer 3, the molar ratio of primer 2, primer 3, and circular DNA structure is 1:1:0.1 to 3, the concentration of primer 2 and primer 3 is 100 to 500 μM, reacting at 40°C for 0.5 to 1h, and obtaining a magnetic nanogel; after dispersing the gel, centrifuging at high speed to remove the solution; 3) adding poly-L-arginine, wherein the molar ratio of the deoxyribonucleic acid nanogel to the poly-L-arginine is 1:1-100; uniformly dispersing by ultrasonication, reacting at 4°C for 12-20 hours, and then removing unreacted poly-L-arginine by high-speed centrifugation; 4) adding clustered regularly interspaced short palindromic repeats-associated genes and guide RNA complexes, wherein the molar ratio of the deoxyribonucleic acid nanogel to the clustered regularly interspaced short palindromic repeats-associated genes is 1:1-10; the molar ratio of the clustered regularly interspaced short palindromic repeats-associated genes to the guide RNA complex is 1:1, reacting overnight at 4°C, and removing unreacted CRISPR-Cas9 and sgRNA complexes by high-speed centrifugation to obtain an enzyme-responsive shearing magnetic DNA nanogel.

6. The method for preparing the enzyme-responsive shearing magnetic DNA nanogel according to claim 5, characterized in that: In step 2), before adding streptavidin-modified ferroferric oxide nanoparticles and biotin-modified deoxyribonucleic acid complexes, cisplatin prodrug is added, and the molar ratio of the deoxyribonucleic acid nanogel to the cisplatin prodrug is 1:30-800.

7. The method for preparing the enzyme-responsive shearing magnetic DNA nanogel according to claim 5, characterized in that: The sequence of the ssDNA is: 5'-Phosphate-TCGTTTGATGTTCCTAACGTACCAACGC ACACGCAGTATTATGGACTGGTAAAAGCTTGACAGGCCCGAAGGAATAGAAGAAG AAGGTGGAGAGAGAGAGGCATTGGCTG-3'; The sequence of primer 1 was: 5′-TAGGAACATCAAACGACAGCCA-3′; The sequence of primer 2 was: 5′-ACGCAGTATTATGGACTG-3′; The sequence of primer 3 is: 5'-TGGTACGTTAGGAACATC-3'.

8. Use of the enzyme-responsive shearing magnetic DNA nanogel according to claim 1 in preparing a drug for treating cancer.

9. The use of the enzyme-responsive shearing magnetic DNA nanogel as claimed in claim 8, characterized in that: The cancer is triple-negative breast cancer.

10. Use of the enzyme-responsive shearing magnetic DNA nanogel according to claim 1 in preparing anti-tumor drug carriers.